Hence, in the current study, we systematically analyzed, according to PRISMA guidelines, the reporting quality of phase II/III RCTs involving migraine patients treated with anti-CGRP MAbs using an adapted version of the 2010 CONSORT statement checklist, thus providing insight into the publicly available information regarding these trials and their potential sources of bias. The gene discussed is CALCA; the disease is migraine disorder.